María Jimena Salcedo-Arellano1,2,3,4, Marisol Wendy Wolf-Ochoa3,4, Tiffany Hong3,4, Sarwat Amina3,4, Flora Tassone2,5, Mirna Lechpammer4, Randi Hagerman1,2, Verónica Martínez-Cerdeño2,3,4. 1. Department of Pediatrics University of California Davis, School of Medicine, Sacramento California USA. 2. Medical Investigation of Neurodevelopmental Disorders Institute (MIND) University of California Davis, Sacramento California USA. 3. Institute for Pediatric Regenerative Medicine and Shriners Hospitals for Children Northern California Sacramento California USA. 4. Department of Pathology and Laboratory Medicine University of California, Davis, School of Medicine Sacramento California USA. 5. Department of Biochemistry and Molecular Medicine University of California Davis, Sacramento California USA.
Abstract
BACKGROUND: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder associated with premutation alleles (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene. FXTAS is characterized by the presence of ubiquitin-positive inclusions in neurons and astrocytes and by cerebellar tremor and ataxia. Parkinsonism has been reported in FXTAS, but most patients lack the characteristic rest tremor and severe rigidity seen in idiopathic Parkinson's disease (PD). OBJECTIVE: To describe the frequency of concomitant PD in FXTAS. METHODS: We reviewed the medical record of 40 deceased patients diagnosed with FXTAS and performed a pathology analysis to confirm both FXTAS and PD. RESULTS: Clinical histories indicated that 5 FXTAS patients were diagnosed with idiopathic PD and 2 with atypical parkinsonian syndrome. After pathological examination, we found that 7 patients in the PD clinical diagnosis group had dopaminergic neuronal loss; however, only 2 of 7 presented Lewy bodies (LBs) in the substantia nigra. Therefore, a total of 5% of the 40 cohort patients met the pathologic criteria for the concomitant diagnosis of FXTAS and PD. In addition, 2 patients not clinically diagnosed with PD also had nigral neuronal loss with LBs in substantia nigra. In total 10% of these 40 patients had LBs. CONCLUSION: This report expands our understanding of clinical symptoms and unusual presentations in patients with FXTAS and the concept that the parkinsonism found in FXTAS is sometimes indistinguishable from PD. We propose that FMR1 should be recognized as one of the exceptional genetic causes of parkinsonism with presynaptic dopaminergic loss and LBs.
BACKGROUND: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder associated with premutation alleles (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene. FXTAS is characterized by the presence of ubiquitin-positive inclusions in neurons and astrocytes and by cerebellar tremor and ataxia. Parkinsonism has been reported in FXTAS, but most patients lack the characteristic rest tremor and severe rigidity seen in idiopathic Parkinson's disease (PD). OBJECTIVE: To describe the frequency of concomitant PD in FXTAS. METHODS: We reviewed the medical record of 40 deceased patients diagnosed with FXTAS and performed a pathology analysis to confirm both FXTAS and PD. RESULTS: Clinical histories indicated that 5 FXTAS patients were diagnosed with idiopathic PD and 2 with atypical parkinsonian syndrome. After pathological examination, we found that 7 patients in the PD clinical diagnosis group had dopaminergic neuronal loss; however, only 2 of 7 presented Lewy bodies (LBs) in the substantia nigra. Therefore, a total of 5% of the 40 cohort patients met the pathologic criteria for the concomitant diagnosis of FXTAS and PD. In addition, 2 patients not clinically diagnosed with PD also had nigral neuronal loss with LBs in substantia nigra. In total 10% of these 40 patients had LBs. CONCLUSION: This report expands our understanding of clinical symptoms and unusual presentations in patients with FXTAS and the concept that the parkinsonism found in FXTAS is sometimes indistinguishable from PD. We propose that FMR1 should be recognized as one of the exceptional genetic causes of parkinsonism with presynaptic dopaminergic loss and LBs.
Authors: Daniel G Healy; Susan Bressman; John Dickson; Laura Silveira-Moriyama; Susanne A Schneider; Sean S O Sullivan; Luke Massey; Kailash P Bhatia; Karen Shaw; Kailash P Bhatia; Jamshed Bomanji; Nicholas W Wood; Andrew J Lees Journal: Mov Disord Date: 2009-06-15 Impact factor: 10.338
Authors: Ronald B Postuma; Daniela Berg; Charles H Adler; Bastiaan R Bloem; Piu Chan; Günther Deuschl; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern Journal: Lancet Neurol Date: 2016-04-11 Impact factor: 44.182
Authors: Mathias Toft; Jan Aasly; Gina Bisceglio; Charles H Adler; Ryan J Uitti; Anna Krygowska-Wajs; Timothy Lynch; Zbigniew K Wszolek; Matthew J Farrer Journal: Mov Disord Date: 2005-02 Impact factor: 10.338
Authors: Sébastien Jacquemont; Randi J Hagerman; Maureen A Leehey; Deborah A Hall; Richard A Levine; James A Brunberg; Lin Zhang; Tristan Jardini; Louise W Gane; Susan W Harris; Kristin Herman; James Grigsby; Claudia M Greco; Elizabeth Berry-Kravis; Flora Tassone; Paul J Hagerman Journal: JAMA Date: 2004-01-28 Impact factor: 56.272
Authors: Aida M Bertoli-Avella; José L Giroud-Benitez; Ali Akyol; Egberto Barbosa; Onno Schaap; Herma C van der Linde; Emilia Martignoni; Leonardo Lopiano; Paolo Lamberti; Emiliana Fincati; Angelo Antonini; Fabrizio Stocchi; Pasquale Montagna; Ferdinando Squitieri; Paolo Marini; Giovanni Abbruzzese; Giovanni Fabbrini; Roberto Marconi; Alessio Dalla Libera; Giorgio Trianni; Marco Guidi; Antonio De Gaetano; Gustavo Boff Maegawa; Antonino De Leo; Virgilio Gallai; Giulia de Rosa; Nicola Vanacore; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink; Vincenzo Bonifati Journal: Mov Disord Date: 2005-04 Impact factor: 10.338
Authors: Maria Jimena Salcedo-Arellano; Desiree Sanchez; Jun Yi Wang; Yingratana A McLennan; Courtney Jessica Clark; Pablo Juarez; Andrea Schneider; Flora Tassone; Randi J Hagerman; Verónica Martínez-Cerdeño Journal: Front Neurosci Date: 2021-09-17 Impact factor: 4.677